ADMA Biologics Statistics
Total Valuation
ADMA Biologics has a market cap or net worth of $1.92 billion. The enterprise value is $2.04 billion.
| Market Cap | 1.92B |
| Enterprise Value | 2.04B |
Important Dates
The last earnings date was Wednesday, May 6, 2026, after market close.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ADMA Biologics has 231.77 million shares outstanding. The number of shares has increased by 3.58% in one year.
| Current Share Class | 231.77M |
| Shares Outstanding | 231.77M |
| Shares Change (YoY) | +3.58% |
| Shares Change (QoQ) | -1.60% |
| Owned by Insiders (%) | 2.12% |
| Owned by Institutions (%) | 91.15% |
| Float | 226.76M |
Valuation Ratios
The trailing PE ratio is 12.17 and the forward PE ratio is 9.22. ADMA Biologics's PEG ratio is 0.32.
| PE Ratio | 12.17 |
| Forward PE | 9.22 |
| PS Ratio | 3.86 |
| Forward PS | 2.89 |
| PB Ratio | 5.06 |
| P/TBV Ratio | 5.10 |
| P/FCF Ratio | 18.26 |
| P/OCF Ratio | 15.35 |
| PEG Ratio | 0.32 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.48, with an EV/FCF ratio of 18.87.
| EV / Earnings | 12.31 |
| EV / Sales | 3.99 |
| EV / EBITDA | 9.48 |
| EV / EBIT | 9.84 |
| EV / FCF | 18.87 |
Financial Position
The company has a current ratio of 6.95, with a Debt / Equity ratio of 0.52.
| Current Ratio | 6.95 |
| Quick Ratio | 3.73 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | 0.94 |
| Debt / FCF | 1.89 |
| Interest Coverage | 28.59 |
Financial Efficiency
Return on equity (ROE) is 43.30% and return on invested capital (ROIC) is 35.80%.
| Return on Equity (ROE) | 43.30% |
| Return on Assets (ROA) | 21.99% |
| Return on Invested Capital (ROIC) | 35.80% |
| Return on Capital Employed (ROCE) | 34.96% |
| Weighted Average Cost of Capital (WACC) | 8.22% |
| Revenue Per Employee | $788,043 |
| Profits Per Employee | $255,570 |
| Employee Count | 647 |
| Asset Turnover | 0.87 |
| Inventory Turnover | 1.00 |
Taxes
In the past 12 months, ADMA Biologics has paid $40.98 million in taxes.
| Income Tax | 40.98M |
| Effective Tax Rate | 19.86% |
Stock Price Statistics
The stock price has decreased by -57.52% in the last 52 weeks. The beta is 0.82, so ADMA Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | -57.52% |
| 50-Day Moving Average | 11.12 |
| 200-Day Moving Average | 15.40 |
| Relative Strength Index (RSI) | 30.53 |
| Average Volume (20 Days) | 7,309,097 |
Short Selling Information
The latest short interest is 20.66 million, so 8.91% of the outstanding shares have been sold short.
| Short Interest | 20.66M |
| Short Previous Month | 19.31M |
| Short % of Shares Out | 8.91% |
| Short % of Float | 9.11% |
| Short Ratio (days to cover) | 3.45 |
Income Statement
In the last 12 months, ADMA Biologics had revenue of $509.86 million and earned $165.35 million in profits. Earnings per share was $0.68.
| Revenue | 509.86M |
| Gross Profit | 312.42M |
| Operating Income | 206.86M |
| Pretax Income | 206.33M |
| Net Income | 165.35M |
| EBITDA | 214.82M |
| EBIT | 206.86M |
| Earnings Per Share (EPS) | $0.68 |
Balance Sheet
The company has $138.15 million in cash and $204.41 million in debt, with a net cash position of -$66.25 million or -$0.29 per share.
| Cash & Cash Equivalents | 138.15M |
| Total Debt | 204.41M |
| Net Cash | -66.25M |
| Net Cash Per Share | -$0.29 |
| Equity (Book Value) | 390.33M |
| Book Value Per Share | 1.68 |
| Working Capital | 437.63M |
Cash Flow
In the last 12 months, operating cash flow was $128.32 million and capital expenditures -$20.42 million, giving a free cash flow of $107.90 million.
| Operating Cash Flow | 128.32M |
| Capital Expenditures | -20.42M |
| Depreciation & Amortization | 7.97M |
| Net Borrowing | 123.59M |
| Free Cash Flow | 107.90M |
| FCF Per Share | $0.47 |
Margins
Gross margin is 61.27%, with operating and profit margins of 40.57% and 32.43%.
| Gross Margin | 61.27% |
| Operating Margin | 40.57% |
| Pretax Margin | 40.47% |
| Profit Margin | 32.43% |
| EBITDA Margin | 42.13% |
| EBIT Margin | 40.57% |
| FCF Margin | 21.16% |
Dividends & Yields
ADMA Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.58% |
| Shareholder Yield | -3.58% |
| Earnings Yield | 8.39% |
| FCF Yield | 5.48% |
Analyst Forecast
The average price target for ADMA Biologics is $19.00, which is 129.75% higher than the current price. The consensus rating is "Buy".
| Price Target | $19.00 |
| Price Target Difference | 129.75% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 11.73% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ADMA Biologics has an Altman Z-Score of 11.46 and a Piotroski F-Score of 5.
| Altman Z-Score | 11.46 |
| Piotroski F-Score | 5 |